CHMP has recommended EU approval of senaparib for advanced ovarian cancer based on FLAMES data.
|Videos|July 7, 2017
Dr. Arend on the PORTEC-3 Trial for Endometrial Cancer
Author(s)Rebecca C. Arend, MD
Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses the PORTEC-3 trial for patients with endometrial cancer.
Advertisement
Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses the PORTEC-3 trial for patients with endometrial cancer.
This trial included patients with high/intermediate risk who received either radiation or radiation plus chemotherapy. According to Arend, if a patient has stage 3 endometrial cancer they should receive chemotherapy.
Advertisement
Related to this article
Advertisement
Advertisement
Trending on OncLive
1
Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
2
FDA Approves Lirafugratinib for Pretreated, Locally Advanced or Metastatic Cholangiocarcinoma
3
FDA Grants Priority Review to Perioperative Durvalumab Plus Neoadjuvant Enfortumab Vedotin in MIBC
4
FDA Approves Belzutifan Plus Lenvatinib for Advanced ccRCC
5